+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Hematologic Malignancies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • PDF Icon

    Report

  • 148 Pages
  • November 2023
  • Region: Global
  • IMARC Group
  • ID: 5901699
Description Jump to:
The global hematologic malignancies market size reached US$ 55.3 Billion in 2022. Looking forward, the publisher expects the market to reach US$ 93.2 Billion by 2028, exhibiting a growth rate (CAGR) of 9.1% during 2022-2028.

Hematologic malignancies, such as lymphoma, leukemia, and multiple myeloma, are cancers of blood-producing cells. These cells comprise platelets for wound clotting, red blood cells (RBCs) to carry oxygen, and white blood cells (WBCs) for immune protection, which originate from hematopoietic stem and progenitor cells in the bone marrow. Hematologic malignancies can be diagnosed using tests like microscopy, cytogenetics, immunophenotyping, flow cytometry, fluorescence in situ hybridization (FISH), polymerase chain reaction (PCR), and gene expression profiling. Nowadays, several drugs, including antitumor antibiotics, histone deacetylase inhibitors, and Janus kinase (JAK) inhibitors, are available around the world for treatment based on diagnostic tests.

Hematologic Malignancies Market Trends:

The incidence of acute myeloid leukemia (AML) is relatively higher among the geriatric population. This, in confluence with the increasing life expectancy, represents one of the key factors catalyzing the demand for hematologic malignancies drugs across the globe. Besides this, with advances in immunohistochemistry (IHC), hematologic malignancies can be diagnosed accurately by exposing tissue samples to various antibodies directed against cell molecules and antigens. This, in turn, is strengthening the growth of the market. Moreover, the rising awareness about early diagnosis, along with improving diagnostic modalities, is contributing to market growth. Apart from this, surgical therapy is available for tissue diagnosis and treatment of lymphoma complications, such as perforation, obstruction, and stricture. This, in confluence with the launch of several novel therapies and multiple label expansions of premium-priced agents, such as CAR T-cell therapies and brexucabtagene autoleuce, is propelling the market growth. Furthermore, ongoing clinical research studies to introduce advanced drugs for patients with advanced hematologic malignancies are anticipated to drive the market in the coming years.

Key Market Segmentation:

The publisher provides an analysis of the key trends in each sub-segment of the global hematologic malignancies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, therapy and end user.

Breakup by Type:

  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Others

Breakup by Therapy:

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

Breakup by End User:

  • Hospitals
  • Diagnostics Centers
  • Research Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report:

  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hematologic Malignancies Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Leukemia
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Lymphoma
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Multiple Myeloma
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Therapy
7.1 Chemotherapy
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Radiotherapy
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Immunotherapy
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Stem Cell Transplantation
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Others
7.5.1 Market Trends
7.5.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Diagnostics Centers
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Research Centers
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Others
8.4.1 Market Trends
8.4.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AbbVie Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 AstraZeneca plc
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Bristol-Myers Squibb Company
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.3.3 Financials
14.3.3.4 SWOT Analysis
14.3.4 Eli Lilly and Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 F. Hoffmann-La Roche Ltd
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 GlaxoSmithKline plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Johnson & Johnson
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Merck & Co. Inc
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Novartis AG
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
14.3.10 Pfizer Inc.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Sanofi S.A.
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Takeda Pharmaceutical Company Limited
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
14.3.12.3 Financials
14.3.12.4 SWOT Analysis
List of Figures
Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2022
Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2022
Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2022
Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2022
Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2017 & 2022
Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2022
Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2023-2028
Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2023-2028
Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 6: Global: Hematologic Malignancies Market: Competitive Structure
Table 7: Global: Hematologic Malignancies Market: Key Players

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A. and Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages148
PublishedNovember 2023
Forecast Period2022 - 2028
Estimated Market Value ( USD ) in 2022 $ 55.3 Billion
Forecasted Market Value ( USD ) by 2028 $ 93.2 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Global Hematologic Malignancies Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis - Product Image

Global Hematologic Malignancies Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • Report
  • 210 Pages
  • Global
From
Global Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Forecast 2024-2030 - Product Image

Global Hematologic Malignancies Testing Market by Product (Consumables, Services, Testing Kits), Technology (Fluorescence In Situ Hybridization, Immunohistochemistry, Next-Generation Sequencing), Disease Type, End-Users - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030 - Product Image

Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography - Product Image

T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography

  • Report
  • 138 Pages
  • Global
From
Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors) - Product Image

Europe T Cell Therapy Market Forecast to 2030 - Regional Analysis - by Modality (Research and Commercialized), Therapy Type [CAR T-cell Therapy and T-cell Receptor (TCR)-based], and Indication (Hematologic Malignancies and Solid Tumors)

  • Report
  • 78 Pages
  • Europe
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.